Curis Receives Milestone Payment From Wyeth
Curis has announced that it has achieved a development milestone in collaboration with one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth. Curis, based in Cambridge, is a therapeutic drug development company. Its technology focuses on the body's regulatory pathways that control repair and regeneration. The milestone is based on Wyeth's and Curis' continued work in preclinical development of Hedgehog pathway agonists for the treatment of stroke and other neurological disorders.
Mass High Tech (http://www.masshightech.com/displayarticledetail.asp?Art_ID=68164)